Status:

COMPLETED

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Lead Sponsor:

Biotronik SE & Co. KG

Conditions:

Atrial Fibrillation

Heart Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. The incidence and prevalence of AF increase exponentially with increasing age and AF is associated with higher ...

Detailed Description

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice; its incidence and prevalence increase exponentially with increasing age and it is associated with increased mor...

Eligibility Criteria

Inclusion

  • Symptomatic paroxysmal or persistent atrial fibrillation
  • Failure or intolerance of antiarrhythmic drug therapy or unwillingness to take antiarrhythmic drugs
  • Left Ventricular Ejection Fraction \<= 35%
  • NYHA \>= II
  • ICD for primary or secondary prevention with atrial sensing capabilities or Cardiac Resynchronization Therapy plus Defibrillator (CRT-D) device, both with Home Monitoring® technology already implanted
  • Patient is willing and able to comply with the protocol and has written informed consent
  • Age \>= 18 years

Exclusion

  • Contraindication for chronic anticoagulation therapy and heparin
  • Documented left atrial diameter \> 6 cm
  • Previous left heart ablation procedure for atrial fibrillation
  • Acute coronary syndrome, cardiac surgery, angioplasty or stroke within 2 months prior to enrollment
  • Untreated hypothyroidism or hyperthyroidism
  • Enrollment in another investigational drug or device study
  • Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age
  • Mental or physical inability to take part in the study
  • Listed for heart transplant
  • Cardiac assist device implanted
  • Planned cardiovascular intervention
  • Life expectancy ≤ 12 months
  • Uncontrolled hypertension
  • Requirement for dialysis due to terminal renal failure
  • Participation in another telemonitoring concept

Key Trial Info

Start Date :

January 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2017

Estimated Enrollment :

398 Patients enrolled

Trial Details

Trial ID

NCT00643188

Start Date

January 1 2008

End Date

March 1 2017

Last Update

May 18 2017

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Royal Adelaide Hospital

Adelaide, Australia

2

Royal Brisbane and Women's Hospital

Herston, Australia

3

A. ö. Krankenhaus der Elisabethinen Linz

Linz, Austria

4

Allgemeines Krankenhaus der Stadt Wien

Vienna, Austria